SCHEMBL4789907

SCHEMBL4789907

CCCCCC1CCN(Cc2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 1/20 0.61
ACHE P22303 7/20 0.60
KCNH2 Q12809 1/20 0.58
ABL1 P00519 1/20 0.58
RIN1 Q13671 1/20 0.58
HRH3 Q9Y5N1 1/20 0.58
BCHE P06276 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12044684 0.98 KCNH2 (0.61) CCR3ACHEKCNH2ABL1RIN1
SCHEMBL12040802 0.98 KCNH2 (0.61) CCR3ACHEKCNH2ABL1RIN1
SCHEMBL8908408 0.95 CCR3 (0.63) CCR3ACHEKCNH2ABL1RIN1
SCHEMBL4499901 0.90 CCR3 (0.69) CCR3ACHEBCHE
SCHEMBL4499239 0.90 CCR3 (0.69) CCR3ACHEBCHE
SCHEMBL69200 0.89 CCR3 (0.67) CCR3ACHEHRH3BCHE
SCHEMBL3107807 0.89 CCR3 (0.71) CCR3ACHEBCHE
SCHEMBL13596997 0.87 KCNH2 (0.56) CCR3ACHEKCNH2ABL1RIN1
SCHEMBL13596970 0.86 HRH3 (0.56) CCR3ACHEKCNH2ABL1RIN1
SCHEMBL7371344 0.86 SIGMAR1 (0.67) CCR3ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2980076-B1 Pyrazolyl derivatives UNIV DUNDEE (GB) 2017-05-31 EP disclosed
EP-1935885-A3 Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. NEUROGEN CORPORATION (US) 2008-10-15 EP disclosed
EP-1935885-A2 Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. NEUROGEN CORPORATION (US) 2008-06-25 EP disclosed
US-7241765-B2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues NEUROGEN CORPORATION (US) 2007-07-10 US disclosed
US-20060229298-A1 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues HUTCHISON ALAN 2006-10-12 US disclosed
US-20060183789-A1 Methods for preventing and treating obesity in patients with mc4 receptor mutations NEUROGEN CORPORATION 2006-08-17 US disclosed
US-7081458-B2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues NEUROGEN CORP. (US) 2006-07-25 US disclosed
CN-1703401-A Substituted 1-benzyl-4-arylpiperazine analogs as ligands for melanin concentrating hormone receptors NEUROGEN CORP (US) 2005-11-30 CN disclosed
US-6953801-B2 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues NEUROGEN CORPORATION (US) 2005-10-11 US disclosed
US-20050182068-A1 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues HUTCHISON ALAN (US) 2005-08-18 US disclosed
US-20050065162-A1 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES NEUROGEN CORPORATION 2005-03-24 US disclosed
WO-2004028453-A2 METHODS FOR PREVENTING AND TREATING OBESITY IN PATIENTS WITH MC4 RECEPTOR MUTATIONS NEUROGEN CORPORATION (US) 2004-04-08 WO disclosed
EP-1389189-A2 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES NEUROGEN CORPORATION (US) 2004-02-18 EP disclosed
WO-2002094799-A3 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES NEUROGEN CORP (US) 2003-11-06 WO disclosed
WO-2002094799-A2 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES NEUROGEN CORPORATION (US) 2002-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229298-A1 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues MCHR1, MCHR2, MC1R CCR3 823/4885ACHE 4359/4885KCNH2 3551/4885
US-20050065162-A1 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES MCHR1, MCHR2, MC1R CCR3 823/4885ACHE 4359/4885KCNH2 3551/4885
US-20050182068-A1 Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues MCHR1, MCHR2, MC1R CCR3 823/4885ACHE 4359/4885KCNH2 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.